Key clinical point: Months after patients cease immune checkpoint inhibitor therapy, immune checkpoint inhibitor–induced inflammatory arthritis can remain active.
Major finding: A majority (53.3%) of patients had active inflammatory arthritis at their last follow-up visit.
Study details: A prospective, observational study of 60 patients referred for inflammatory arthritis associated with immune checkpoint inhibitors.
Disclosures: The study was funded via a grant from Bristol-Myers Squibb, an arthritis fellowship award from AbbVie, and additional financial support from the Camille Julia Morgan Arthritis Research and Education Fund, the Jerome L. Greene Foundation, and the National Institutes of Health. The authors reported various conflicts of interest, including receiving honoraria, grants, and research funding from numerous pharmaceutical companies.
Braaten TJ et al. Ann Rheum Dis. 2019 Sep 20. doi: 10.1136/annrheumdis-2019-216109.